<DOC>
	<DOCNO>NCT02986451</DOCNO>
	<brief_summary>This phase II study investigate efficacy safety combination biaxin , lenalidomide dexamethasone subject relapsed/refractory MM .</brief_summary>
	<brief_title>Clarithromycin , Lenalidomide Dexamethasone Relapsed/Refractory Myeloma</brief_title>
	<detailed_description>The combination lenalidomide dexamethasone effective increase response rate , time progression , overall survival patient relapse refractory myeloma.Clarithromycin antibiotic show efficacy association steroid lenalidomide.Clarithromycin , lenalidomide dexamethasone ( BiRd ) newly diagnose MM yield overall response rate ( ORR ) 93 % progression-free survival ( PFS ) 43 months.No prospective study BiRd treat relapse refractory myeloma report far.The goal phase 2 clinical trial assess response rate toxicity combination regimen clarithromycin ( Biaxin ) , lenalidomide ( Revlimid ) , dexamethasone ( BiRD ) treatment relapsed/refractory MM .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Patient previous diagnosis multiple myeloma Patient require retreatment multiple myeloma Subject measurable disease define &gt; 0.5 g/dL serum monoclonal protein , &gt; 10 mg/dL involve serum free light chain ( either kappa lambda ) provide serum free light chain ratio abnormal , &gt; 0.2 g/24 hr urinary Mprotein excretion , and/or measurable plasmacytoma ( ) least 1cm great dimension measure either CT scan MRI Subject Karnofsky performance status ≥60 % ( &gt; 50 % due bony involvement myeloma ( see Appendix IV ) Subject life expectancy ≥ 3 month Subjects must meet follow laboratory parameter : Absolute neutrophil count ( ANC ) ≥750 cells/mm3 ( 1.0 x 109/L ) Hemoglobin ≥ 7 g/dL Platelet count ≥ 75,000/mm3 ( 30 x 109/L extensive bone marrow infiltration ) Serum SGOT/AST &lt; 3.0 x upper limit normal ( ULN ) Serum SGPT/ALT &lt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &lt; 2.0 mg/dL ( 34 µmol/L ) Creatinine clearance ≥ 30 cc/min Subject immeasurable MM ( measurable monoclonal protein , free light chain blood urine , measureable plasmacytoma radiologic scan ) Subject prior history malignancy unless diseasefree ≥ 5 year , except basal cell squamous cell carcinoma skin , carcinoma situ cervix breast , localized prostate cancer Gleason score &lt; 7 stable prostate specific antigen ( PSA ) level Subject myocardial infarction within 6 month prior enrollment , NYHA ( New York Hospital Association ) Class III IV heart failure ( see Appendix VI ) , Ejection Fraction &lt; 35 % , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities Female subject pregnant lactating Subject know HIV infection Subject know active hepatitis B hepatitis C infection Subject active viral bacterial infection coexist medical problem would significantly increase risk treatment program Subject unable reliably take oral medication Subject know hypersensitivity dexamethasone , cyclophosphamide , paclitaxel Subject history thromboembolic event within past 4 week prior enrollment Subject clinically significant medical psychiatric disease condition , investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>